Considering that WDR72 was a significant indicator for prognosis of ccRCC, we investigated the relationship between the expression level of WDR72 and the outcome of ccRCC patients treated with Nivolumab, a classical drug of immune checkpoint inhibitor (ICI). The gene discussed is WDR72; the disease is nonpapillary renal cell carcinoma.